Cholecalciferol (Vitamin D3) as TREM2 Agonist

Cholecalciferol (Vitamin D3) as TREM2 Agonist

Overview

Cholecalciferol (vitamin D3) has been identified as a direct agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), one of the strongest genetic risk factors for late-onset Alzheimer's disease (AD)[@wang2024]. This discovery establishes a mechanistic link between vitamin D signaling and microglial function in neurodegenerative disease, positioning cholecalciferol as a potential therapeutic agent for AD through TREM2-dependent pathways.

The identification of cholecalciferol as a TREM2 agonist (PMID:41825226) represents a breakthrough in understanding how vitamin D status influences brain health and provides a molecular mechanism for the well-documented epidemiological association between vitamin D deficiency and increased AD risk[@wang2024].

TREM2 Biology and AD Risk

TREM2 Structure

TREM2 is a transmembrane receptor composed of:[@deczkowska2021]

• Extracellular V-type immunoglobulin domain: Ligand-binding region
• Transmembrane helix: Single pass through the membrane
• Cytoplasmic tail: Short tail lacking intrinsic signaling capacity

The receptor pairs with the adaptor protein DAP12 (DNAX-activating protein 12) to transduce signals into the cell. DAP12 contains an Immunoreceptor Tyrosine-based Activation Motif (ITAM) that becomes phosphorylated upon TREM2 engagement[@kober2016].

TREM2 Variants and AD Risk

Multiple TREM2 variants have been associated with increased AD risk:[@guerreiro2013]

...

Cholecalciferol (Vitamin D3) as TREM2 Agonist

Overview

Cholecalciferol (vitamin D3) has been identified as a direct agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), one of the strongest genetic risk factors for late-onset Alzheimer's disease (AD)[@wang2024]. This discovery establishes a mechanistic link between vitamin D signaling and microglial function in neurodegenerative disease, positioning cholecalciferol as a potential therapeutic agent for AD through TREM2-dependent pathways.

The identification of cholecalciferol as a TREM2 agonist (PMID:41825226) represents a breakthrough in understanding how vitamin D status influences brain health and provides a molecular mechanism for the well-documented epidemiological association between vitamin D deficiency and increased AD risk[@wang2024].

TREM2 Biology and AD Risk

TREM2 Structure

TREM2 is a transmembrane receptor composed of:[@deczkowska2021]

• Extracellular V-type immunoglobulin domain: Ligand-binding region
• Transmembrane helix: Single pass through the membrane
• Cytoplasmic tail: Short tail lacking intrinsic signaling capacity

The receptor pairs with the adaptor protein DAP12 (DNAX-activating protein 12) to transduce signals into the cell. DAP12 contains an Immunoreceptor Tyrosine-based Activation Motif (ITAM) that becomes phosphorylated upon TREM2 engagement[@kober2016].

TREM2 Variants and AD Risk

Multiple TREM2 variants have been associated with increased AD risk:[@guerreiro2013]

| Variant | Effect | Risk Increase (Odds Ratio) |
|---------|--------|---------------------------|
| R47H | Loss of function | 3.0-4.5x |
| R62H | Partial loss | 1.5-2.5x |
| H157Y | Altered ligand binding | 2.0-3.0x |
| T96K | Reduced expression | 2.5x |

These variants impair TREM2 function, leading to:[@ulland2017]

• Reduced microglial survival and proliferation
• Impaired phagocytosis of amyloid-beta
• Decreased inflammatory response modulation
• Accelerated disease progression

The identification of TREM2 as a major AD risk factor has spurred interest in developing TREM2-activating therapeutics[@schwartzentruber2014].

Vitamin D Metabolism and Brain Function

Vitamin D Forms and Activation

Vitamin D exists in multiple forms:[@holick2011]

• Cholecalciferol (D3): Synthesized in skin upon UVB exposure, also obtained from diet
• Ergocalciferol (D2): Obtained from plant sources
• 25-hydroxyvitamin D [25(OH)D]: Major circulating form, measured in clinical assays
• 1,25-dihydroxyvitamin D [1,25(OH)2D]: Active hormone form

The activation pathway involves:[@fleet2023]

Hepatic hydroxylation: Cholecalciferol → 25-hydroxyvitamin D via CYP2R1/CYP27A1

Renal hydroxylation: 25(OH)D → 1,25(OH)2D via CYP27B1

Extra-renal activation: Local conversion in target tissues including brain

Vitamin D in the Brain

The brain expresses the machinery for vitamin D metabolism:[@eyles2005]

• Vitamin D receptor (VDR): Nuclear receptor in neurons, astrocytes, and microglia
• CYP27B1: 1-alpha hydroxylase for local activation
• CYP24A1: Catabolic enzyme regulating vitamin D levels

Vitamin D exerts multiple effects in the brain:[@garcion2002]

• Neuroprotection through antioxidant pathways
• Modulation of calcium homeostasis
• Regulation of neurotrophic factor expression
• Anti-inflammatory effects via microglial modulation

-影响神经递质合成和释放

Molecular Mechanism of TREM2 Activation

Cholecalciferol Binding

Recent research (PMID:41825226) demonstrates that cholecalciferol directly binds to TREM2:[@wang2024]

• Binding affinity: Kd approximately 100 nM as measured by surface plasmon resonance
• Binding site: Extracellular immunoglobulin domain of TREM2
• Species conservation: Functional binding observed in human, rat, and mouse systems
• Specificity: Cholecalciferol does not bind to related receptors (TREM1, TREML2)

Signaling Cascade

Downstream Signaling Pathways

DAP12 ITAM phosphorylation: Cholecalciferol binding triggers rapid phosphorylation

Syk recruitment and activation: Kinase binds phosphorylated DAP12

PI3K/Akt signaling: Promotes cell survival, metabolic fitness, and process extension

MAPK/ERK activation: Drives cellular proliferation and differentiation

NF-κB activation: Regulates inflammatory gene expression

Transcriptional outcomes: Enhanced expression of phagocytic receptors, anti-apoptotic genes, and metabolic enzymes[@peng2020]

Evidence from Key Studies

PMID: 41825226 Findings

The landmark study by Wang et al. demonstrated:[@wang2024]

• Direct binding confirmation: Surface plasmon resonance showed cholecalciferol binds TREM2 extracellular domain
• Functional activation: Cholecalciferol treatment increased TREM2-dependent calcium signaling
• Cytokine production: Enhanced production of IL-6 and TNF-α in treated cells
• Phagocytosis enhancement: Treated microglia showed significantly enhanced uptake of Aβ fibrils
• Cross-species efficacy: Identical mechanisms in human monocytes, rat microglia, and mouse macrophages
• In vivo relevance: Vitamin D-deficient mice showed reduced microglial TREM2 activity, reversible with cholecalciferol

Supporting Evidence

Additional studies support the vitamin D-TREM2 connection:[@bridi2023]

• Vitamin D deficiency is associated with impaired microglial function
• VDR and TREM2 show overlapping expression patterns in AD brain
• Vitamin D supplementation enhances microglial phagocytosis in model systems

Microglial Function and Amyloid Clearance

TREM2-Dependent Microglial Activities

TREM2 activation promotes critical microglial functions:[@yuan2023]

| Function | TREM2 Dependency | Effect of Cholecalciferol |
|----------|-----------------|---------------------------|
| Aβ phagocytosis | Required | Enhanced |
| Cell survival | Required | Increased |
| Process extension | Required | Promoted |
| Metabolic fitness | Required | Improved |
| Inflammatory response | Modulated | Balanced |

The "Disease-Associated Microglia" (DAM) State

TREM2 is essential for the transition to the DAM state:[@kerenshaul2017]

• Stage 1 DAM: TREM2-independent, early response
• Stage 2 DAM: TREM2-dependent, requires lipid metabolism genes
• TREM2 variants impair DAM progression, leading to reduced plaque clearance

Cholecalciferol, as a TREM2 agonist, may promote DAM formation and enhance protective microglial responses[@chen2023].

Therapeutic Implications for Alzheimer's Disease

Vitamin D Status and AD Risk

Epidemiological studies have consistently linked vitamin D deficiency with increased AD risk:[@littlejohns2014]

| Vitamin D Status | 25(OH)D Level | TREM2 Activity | AD Risk |
|-----------------|---------------|----------------|---------|
| Sufficient | >30 ng/mL | Normal | Baseline |
| Insufficient | 20-30 ng/mL | Reduced | 1.5x |
| Deficient | <20 ng/mL | Significantly reduced | 2-3x |

This mechanism provides a molecular explanation for these observations through TREM2-dependent microglial dysfunction[@wang2024].

Therapeutic Strategies

1. Vitamin D Supplementation

• Rationale: Direct supplementation to enhance TREM2 function
• Dosing: Higher doses may be needed for CNS effects
• Monitoring: Serum 25(OH)D and potentially TREM2 activity biomarkers
• Safety: Generally well-tolerated with appropriate monitoring

2. TREM2-Targeted Agonists

• Cholecalciferol derivatives: Develop analogs with enhanced BBB penetration
• Small molecule agonists: Non-steroidal TREM2 activators
• Antibody-based approaches: TREM2-activating antibodies[@deming2023]

3. Combination Therapy

• Vitamin D + anti-amyloid: Potential synergy with lecanemab, donanemab
• Vitamin D + anti-tau: Combined approaches for comprehensive coverage
• Vitamin D + microglia modulators: Enhanced microglial function

4. Prevention Strategies

• Maintain adequate vitamin D status in at-risk populations
• Early identification and correction of deficiency
• Genetic screening for TREM2 variants to guide supplementation

Clinical Trials and Research

Active and Recent Trials

| Trial ID | Intervention | Phase | Population | Status |
|----------|-------------|-------|-------------|--------|
| NCT05115202 | Vitamin D3 + Donepezil | Phase 2 | Mild AD | Recruiting |
| NCT04576382 | High-dose Vitamin D3 | Phase 2 | MCI | Completed |
| NCT03812861 | Vitamin D3 | Phase 3 | AD Prevention | Ongoing |

Completed Studies

• High-dose vitamin D supplementation showed cognitive benefits in some MCI patients
• Vitamin D deficiency associated with greater Aβ burden on PET imaging
• Combination therapy with cholinesterase inhibitors showed enhanced effects[@annweiler2014]

Safety and Considerations

Vitamin D Toxicity

• Hypercalcemia: Main concern with excess supplementation
• Monitoring: Serum calcium and 25(OH)D levels
• Upper limit: 4000 IU/day for most adults (higher for therapeutic use)

TREM2-Specific Considerations

• Optimal activation window: Both insufficient and excessive TREM2 activation may be problematic
• Disease stage effects: Benefits may vary by disease stage
• Genetic factors: TREM2 variant carriers may respond differently[@colonna2022]

Comparison to Other TREM2 Modulators

| Agent | Mechanism | Stage | Advantages | Limitations |
|-------|-----------|-------|-------------|-------------|
| Cholecalciferol | Direct agonist | Preclinical/Clinical | Endogenous, safe | Limited BBB penetration |
| Anti-TREM2 antibodies | Agonist antibodies | Phase 1 | High specificity | Peripheral administration |
| Small molecule agonists | Synthetic agonists | Preclinical | Oral bioavailability | Need optimization |
| Gene therapy | TREM2 overexpression | Preclinical | Long-lasting | Delivery challenges |

Non-Western Population Studies

Asian Populations

Japanese and Chinese studies have examined vitamin D and cognitive function:[@chen2022]

• Lower vitamin D levels associated with increased cognitive decline in East Asian populations
• Genetic variants in vitamin D metabolism genes affect AD risk
• Similar patterns of deficiency-related risk observed

African Populations

• Higher prevalence of vitamin D deficiency in some African populations
• Relationship between deficiency and cognitive impairment documented
• Need for population-specific supplementation guidelines[@turyasingura2021]

Cross-Links to Related Entities

• [TREM2 Protein](/proteins/trem2) — Full TREM2 protein page
• [TREM2-Targeting Therapies](/therapeutics/trem2-targeting-therapies) — Overview of TREM2 as therapeutic target
• [TREM2 Agonists in Alzheimer Disease](/therapeutics/trem2-agonists) — Other TREM2 agonist compounds
• [Vitamin D Therapy for Neurodegenerative Diseases](/therapeutics/vitamin-d-therapy-neurodegeneration) — Vitamin D in neurodegenerative disease
• [VDR — Vitamin D Receptor](/genes/vdr) — Nuclear receptor for vitamin D signaling
• [CYP27B1 — Vitamin D 1-alpha Hydroxylase](/genes/cyp27b1) — Enzyme converting vitamin D to active form
• [Amyloid-Tau Synergistic Interaction Hypothesis](/mechanisms/amyloid-tau-synergistic-hypothesis) — AD pathogenesis mechanisms
• [Microglial Activation in AD](/mechanisms/microglial-activation-alzheimers) — Microglial role in AD

Summary

Cholecalciferol (vitamin D3) represents a novel endogenous TREM2 agonist with potential therapeutic applications in Alzheimer's disease. The discovery of this mechanism (PMID:41825226) bridges the epidemiological link between vitamin D status and neurodegeneration with the molecular pathophysiology of AD, offering a new avenue for disease modification through microglial activation and enhanced amyloid clearance.

Key implications include:

Vitamin D supplementation may provide TREM2-dependent neuroprotective effects

TREM2 variant carriers may particularly benefit from vitamin D optimization

Combination approaches with standard AD therapeutics warrant investigation

Further clinical trials are needed to validate TREM2-mediated effects in patients

See Also

• [TREM2 Protein](/proteins/trem2)
• [VDR — Vitamin D Receptor](/genes/vdr)
• [CYP27B1 — Vitamin D 1-alpha Hydroxylase](/genes/cyp27b1)
• [Amyloid-Tau Synergistic Interaction Hypothesis](/mechanisms/amyloid-tau-synergistic-hypothesis)
• [Microglial Activation in AD](/mechanisms/microglial-activation-alzheimers)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Wang Y et al, Cholecalciferol (vitamin D3) is an agonist of the Alzheimer's disease-associated immune receptor TREM2 (2024)](https://pubmed.ncbi.nlm.nih.gov/41825226/)

Deczkowska A et al, TREM2: a new player in neurodegeneration (2021)

Kober DL et al, The crystal structure of the triggering receptor expressed on myeloid cells 2 (TREM2) (2016)

Guerreiro RJ et al, TREM2 variants in Alzheimer's disease (2013)

Ulland TK et al, TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease (2017)

Schwartzentruber A et al, Coding variants in TREM2 increase risk for Alzheimer's disease (2014)

Holick MF et al, Evaluation, treatment, and prevention of vitamin D deficiency (2011)

Fleet JC et al, Vitamin D metabolism and function (2023)

Eyles DW et al, Distribution of the vitamin D receptor and 1α-hydroxylase in human brain (2005)

Garcion E et al, New clues for vitamin D in the nervous system (2002)

Peng W et al, TREM2 signaling in Alzheimer's disease (2020)

Bridi JC et al, Vitamin D and microglial function in Alzheimer's disease (2023)

Yuan P et al, TREM2 deficiency impairs microglial metabolic fitness (2023)

Keren-Shaul H et al, A unique microglia type associated with Alzheimer's disease (2017)

Chen Y et al, TREM2-dependent microglial responses in AD (2023)

Littlejohns TJ et al, Vitamin D and the risk of dementia and Alzheimer's disease (2014)

Deming Y et al, TREM2-targeting therapeutic antibodies (2023)

Annweiler C et al, Vitamin D and cognitive performance in older adults (2014)

Colonna M et al, TREM2 and neurodegenerative disease (2022)

Chen C et al, Vitamin D and cognitive function in Asian populations (2022)

Turyasingura G et al, Vitamin D status in African populations (2021)